Bluejay_primary_logo.png
Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19. Dezember 2024 12:04 ET | Bluejay Therapeutics
REDWOOD CITY, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and...
Bluejay_primary_logo.png
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors
21. November 2024 09:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other...
Bluejay_primary_logo.png
Bluejay Therapeutics Reports Best-in-Class Monoclonal Antibody BJT-778 Achieved 100% Virologic Response and Up To 78% Combined Virologic Response and ALT Normalization as Monotherapy in Participants With Chronic Hepatitis D (CHD)
15. November 2024 11:00 ET | Bluejay Therapeutics
Phase 2 study results to be presented at The Liver Meeting® 2024 of AASLD BJT-778 900 mg dosed every four weeks showed promising efficacy by Week 24: 100% virologic response with 50% of participants...
Bluejay_primary_logo.png
Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress
05. Juni 2024 08:00 ET | Bluejay Therapeutics
100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and composite response BJT-778 was well tolerated across all arms at doses...
Bluejay_primary_logo.png
Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D
29. Mai 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today...
Bluejay_primary_logo.png
Bluejay Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver (EASL) Congress 2024
22. Mai 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics today announced it will present new data from its ongoing Phase 2 trial evaluating the potential of BJT-778, an...
Bluejay_primary_logo.png
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
09. Mai 2024 07:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C...
Bluejay_primary_logo.png
Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection
25. März 2024 08:00 ET | Bluejay Therapeutics
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European...
Bluejay_primary_logo.png
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
21. September 2023 07:55 ET | Bluejay Therapeutics
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc. a private clinical stage biopharmaceutical company focused on viral and liver diseases, today announced the...
Bluejay_primary_logo.png
Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment
01. Juni 2023 18:14 ET | Bluejay Therapeutics
SAN MATEO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a company dedicated to developing innovative treatments for viral and liver diseases, announces the successful completion...